Literature DB >> 1322500

Raf-1 activates MAP kinase-kinase.

J M Kyriakis1, H App, X F Zhang, P Banerjee, D L Brautigan, U R Rapp, J Avruch.   

Abstract

The normal cellular homologue of the acutely transforming oncogene v-raf is c-raf-1, which encodes a serine/threonine protein kinase that is activated by many extracellular stimuli. The physiological substrates of the protein c-Raf-1 are unknown. The mitogen-activated protein (MAP) kinases Erk1 and 2 are also activated by mitogens through phosphorylation of Erk tyrosine and threonine residues catalysed by a protein kinase of relative molecular mass 50,000, MAP kinase-kinase (MAPK-K). Here we report that MAPK-K as well as Erk1 and 2 are constitutively active in v-raf-transformed cells. MAPK-K partially purified from v-raf-transformed cells or from mitogen-treated cells can be deactivated by phosphatase 2A. c-Raf-1 purified after mitogen stimulation can reactivate the phosphatase 2A-inactivated MAPK-K over 30-fold in vitro. c-Raf-1 reactivation of MAPK-K coincides with the selective phosphorylation at serine/threonine residues of a polypeptide with M(r) 50,000 which coelutes precisely on cation-exchange chromatography with the MAPK-K activatable by c-Raf-1. These results indicate that c-Raf-1 is an immediate upstream activator of MAPK-K in vivo. To our knowledge, MAPK-K is the first physiological substrate of the c-raf-1 protooncogene product to be identified.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322500     DOI: 10.1038/358417a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  323 in total

1.  Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis.

Authors:  S Kraus; R Seger; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

Review 2.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Mitogen-activated protein kinases: specific messages from ubiquitous messengers.

Authors:  H J Schaeffer; M J Weber
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 4.  Regulation of ion channel expression in neural cells by hormones and growth factors.

Authors:  L J Chew; V Gallo
Journal:  Mol Neurobiol       Date:  1998-12       Impact factor: 5.590

Review 5.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

Authors:  W Kolch
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 6.  Ethylene biosynthesis and signaling networks.

Authors:  Kevin L-C Wang; Hai Li; Joseph R Ecker
Journal:  Plant Cell       Date:  2002       Impact factor: 11.277

7.  Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association.

Authors:  M T Yip-Schneider; W Miao; A Lin; D S Barnard; G Tzivion; M S Marshall
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

8.  In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.

Authors:  Masanori Kurimoto; Yutaka Hirashima; Hideo Hamada; Hironaga Kamiyama; Shoichi Nagai; Nakamasa Hayashi; Shunro Endo
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

9.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

10.  Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages.

Authors:  B W Winston; C A Lange-Carter; A M Gardner; G L Johnson; D W Riches
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.